UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 97

of 'Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia'

97
TI
Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.
AU
Tefferi A, Letendre L
SO
Am J Hematol. 2011 Jul;86(7):610-1. Epub 2011 May 31.
 
AD
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. tefferi.ayalew@mayo.edu
PMID